Quoin Pharmaceuticals, Ltd.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Quoin Pharmaceuticals is a clinical-stage pharmaceutical company developing treatments for rare and orphan diseases, including skin disorders such as Netherton Syndrome and epidermolysis bullosa.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Carter Denise P.Chief Operating Officer | Buy | $100K | 20,490at $4.88 | Aug 31, 2026 |
| Myers MichaelChief Executive Officer | Buy | $100K | 20,490at $4.88 | Aug 31, 2026 |
| Lawlor Sally BridgetChief Financial Officer | Buy | $50K | 10,244at $4.88 | Aug 31, 2026 |
| Culverwell Anthony JamesDirector | Buy | $30K | 6,146at $4.88 | Aug 31, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable QNRX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.